Moderna

Mar 03, 2020

Aggressive Infectious Diseases Prompt the Development of Powerful New Blood Tests

Jan 14, 2020

Global Neoantigen Cancer Vaccine Market Study, 2023-2030: Projecting a CAGR of 34.69%; Generating Revenues of $227.1M in 2023 and $1.82B in 2030

Dec 19, 2019

Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Dec 16, 2019

Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

Dec 10, 2019

Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

Dec 02, 2019

Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Oct 08, 2019

Flagship Pioneering Unveils Cygnal Therapeutics

Sep 12, 2019

Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

Jul 10, 2019

Visiongain Report Offers Transformative Insights on the $5.5bn mRNA Vaccines and Therapeutics Market

Apr 16, 2019

Flagship Pioneering Unveils Kintai Therapeutics and Appoints Pharmaceutical Drug Developer Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer

Jan 09, 2019

Why Clinical Trial Advantages and Regulatory Process in EU may Hold Advantages Over the U.S.

Jan 08, 2019

Cygnal Therapeutics Appoints Pearl S. Huang as Chief Executive Officer